These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 12238094)

  • 1. [Glucagon-like peptide-1 (GLP-1) receptor].
    Taminato T
    Nihon Rinsho; 2002 Jul; 60 Suppl 7():535-41. PubMed ID: 12238094
    [No Abstract]   [Full Text] [Related]  

  • 2. The glucagon-like peptides: a double-edged therapeutic sword?
    Perry T; Greig NH
    Trends Pharmacol Sci; 2003 Jul; 24(7):377-83. PubMed ID: 12871671
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [GIP and GLP-1: multiplicity of regulator mechanisms for insulin secretion].
    Thorens B
    Journ Annu Diabetol Hotel Dieu; 2004; ():111-25. PubMed ID: 15259310
    [No Abstract]   [Full Text] [Related]  

  • 5. ["Glucagon-like peptide I": a therapeutic alternative for diabetes mellitus?].
    Fehmann HC; Göke B
    Dtsch Med Wochenschr; 1994 Feb; 119(8):275-9. PubMed ID: 8112212
    [No Abstract]   [Full Text] [Related]  

  • 6. Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
    Sinclair EM; Drucker DJ
    Physiology (Bethesda); 2005 Oct; 20():357-65. PubMed ID: 16174875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
    Gefel D; Barg Y; Zimlichman R
    Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Incretin research in the development of new strategies of diabetes therapy].
    Göke B; Göke R; Fehmann HC; Arnold R
    Internist (Berl); 1995 Apr; 36(4):343-9. PubMed ID: 7775082
    [No Abstract]   [Full Text] [Related]  

  • 9. GLP-1: target for a new class of antidiabetic agents?
    Edwards CM
    J R Soc Med; 2004 Jun; 97(6):270-4. PubMed ID: 15173327
    [No Abstract]   [Full Text] [Related]  

  • 10. Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of type 2 diabetes.
    Rachman J
    Diabet Med; 2004 Jan; 21 Suppl 1():18-20. PubMed ID: 15088933
    [No Abstract]   [Full Text] [Related]  

  • 11. Central glucagon-like peptide-I in the control of feeding.
    Gunn I; O'Shea D; Turton MD; Beak SA; Bloom SR
    Biochem Soc Trans; 1996 May; 24(2):581-4. PubMed ID: 8736807
    [No Abstract]   [Full Text] [Related]  

  • 12. Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action.
    Scrocchi LA; Hill ME; Saleh J; Perkins B; Drucker DJ
    Diabetes; 2000 Sep; 49(9):1552-60. PubMed ID: 10969840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1.
    Li Y; Cao X; Li LX; Brubaker PL; Edlund H; Drucker DJ
    Diabetes; 2005 Feb; 54(2):482-91. PubMed ID: 15677506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide 1 excites hypocretin/orexin neurons by direct and indirect mechanisms: implications for viscera-mediated arousal.
    Acuna-Goycolea C; van den Pol A
    J Neurosci; 2004 Sep; 24(37):8141-52. PubMed ID: 15371515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites.
    Yamamoto H; Kishi T; Lee CE; Choi BJ; Fang H; Hollenberg AN; Drucker DJ; Elmquist JK
    J Neurosci; 2003 Apr; 23(7):2939-46. PubMed ID: 12684481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.
    Holz GG; Chepurny OG
    Curr Med Chem; 2003 Nov; 10(22):2471-83. PubMed ID: 14529486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
    Nielsen LL; Young AA; Parkes DG
    Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM.
    Thorens B; Waeber G
    Diabetes; 1993 Sep; 42(9):1219-25. PubMed ID: 8349031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 is a physiological incretin in rat.
    Wang Z; Wang RM; Owji AA; Smith DM; Ghatei MA; Bloom SR
    J Clin Invest; 1995 Jan; 95(1):417-21. PubMed ID: 7814643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in the biology of the glucagon-like peptides GLP-1 and GLP-2.
    Drucker DJ; Lovshin J; Baggio L; Nian M; Adatia F; Boushey RP; Liu Y; Saleh J; Yusta B; Scrocchi L
    Ann N Y Acad Sci; 2000; 921():226-32. PubMed ID: 11193827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.